PDF(Pubmed)
Abstract：
UNASSIGNED: The objective of this study was to estimate the annual incidence rates of herpes zoster (HZ) and postherpetic neuralgia (PHN) among individuals aged ≥19 years and the proportion who received HZ vaccination among those aged ≥50 years.
UNASSIGNED: This observational cohort study was conducted with administrative claims data from HealthVerity and included insured individuals across the US. Crude and US age- and sex-standardized incidence rates of HZ and PHN were calculated from 1 January 2019 to 31 May 2022 by calendar year in persons aged ≥19 years. Outcomes were defined as ≥1 ICD-10 diagnosis code for HZ or PHN. Analyses were stratified by age, sex, and immunocompromised status. Among those aged ≥50 years, the proportion who received 1 or 2 doses of recombinant zoster vaccine (Shingrix) or 1 dose of Zostavax was calculated.
UNASSIGNED: Standardized annual incidence rates from 2019 to 2021 were 542 to 685 per 100 000 person-years for HZ and 35 to 38 per 100 000 person-years for PHN. Rates were highest among females, older adults, and individuals who were immunocompromised. From 1 January 2019 to 31 May 2022, 4.3% and 9.0% of persons aged ≥50 years received 1 and 2 doses of Shingrix, respectively, and 0.2% received 1 dose of Zostavax.
UNASSIGNED: In this US claims database analysis, HZ and PHN were more frequent among older adults, females, and individuals who were immunocompromised. Between 1 January 2019 and 31 May 2022, 9% of persons aged ≥50 years received 2 doses of the Shingrix vaccine. Greater efforts are needed to increase vaccine uptake against HZ, especially for those at highest risk.
UNASSIGNED: This observational cohort study was conducted with administrative claims data from HealthVerity and included insured individuals across the US. Crude and US age- and sex-standardized incidence rates of HZ and PHN were calculated from 1 January 2019 to 31 May 2022 by calendar year in persons aged ≥19 years. Outcomes were defined as ≥1 ICD-10 diagnosis code for HZ or PHN. Analyses were stratified by age, sex, and immunocompromised status. Among those aged ≥50 years, the proportion who received 1 or 2 doses of recombinant zoster vaccine (Shingrix) or 1 dose of Zostavax was calculated.
UNASSIGNED: Standardized annual incidence rates from 2019 to 2021 were 542 to 685 per 100 000 person-years for HZ and 35 to 38 per 100 000 person-years for PHN. Rates were highest among females, older adults, and individuals who were immunocompromised. From 1 January 2019 to 31 May 2022, 4.3% and 9.0% of persons aged ≥50 years received 1 and 2 doses of Shingrix, respectively, and 0.2% received 1 dose of Zostavax.
UNASSIGNED: In this US claims database analysis, HZ and PHN were more frequent among older adults, females, and individuals who were immunocompromised. Between 1 January 2019 and 31 May 2022, 9% of persons aged ≥50 years received 2 doses of the Shingrix vaccine. Greater efforts are needed to increase vaccine uptake against HZ, especially for those at highest risk.
摘要：
■这项研究的目的是估计年龄≥19岁的个体中带状疱疹（HZ）和带状疱疹后遗神经痛（PHN）的年发病率以及年龄≥50岁的个体中接受HZ疫苗接种的比例。
这项观察性队列研究是根据HealthVerity的行政索赔数据进行的，包括美国各地的被保险人。从2019年1月1日至2022年5月31日，按日历年计算≥19岁人群中HZ和PHN的粗和美国年龄和性别标准化发病率。结果定义为HZ或PHN的≥1个ICD-10诊断代码。分析按年龄分层，性别,和免疫受损状态。在年龄≥50岁的人群中，计算接受1或2剂重组带状疱疹疫苗(Shingrix)或1剂Zostavax的比例.
■从2019年到2021年，HZ的标准化年发病率为每10万人年542至685，PHN为每10万人年35至38。女性的比率最高，老年人,和免疫功能低下的人。从2019年1月1日至2022年5月31日，4.3%和9.0%的年龄≥50岁的人接受了1剂和2剂Shingrix，分别,0.2%接受了1剂Zostavax。
■在此美国索赔数据库分析中，HZ和PHN在老年人中更常见，女性,和免疫功能低下的人。在2019年1月1日至2022年5月31日之间，9％的年龄≥50岁的人接受了2剂Shingrix疫苗。需要做出更大的努力来增加针对HZ的疫苗摄取，尤其是那些风险最高的人。
这项观察性队列研究是根据HealthVerity的行政索赔数据进行的，包括美国各地的被保险人。从2019年1月1日至2022年5月31日，按日历年计算≥19岁人群中HZ和PHN的粗和美国年龄和性别标准化发病率。结果定义为HZ或PHN的≥1个ICD-10诊断代码。分析按年龄分层，性别,和免疫受损状态。在年龄≥50岁的人群中，计算接受1或2剂重组带状疱疹疫苗(Shingrix)或1剂Zostavax的比例.
■从2019年到2021年，HZ的标准化年发病率为每10万人年542至685，PHN为每10万人年35至38。女性的比率最高，老年人,和免疫功能低下的人。从2019年1月1日至2022年5月31日，4.3%和9.0%的年龄≥50岁的人接受了1剂和2剂Shingrix，分别,0.2%接受了1剂Zostavax。
■在此美国索赔数据库分析中，HZ和PHN在老年人中更常见，女性,和免疫功能低下的人。在2019年1月1日至2022年5月31日之间，9％的年龄≥50岁的人接受了2剂Shingrix疫苗。需要做出更大的努力来增加针对HZ的疫苗摄取，尤其是那些风险最高的人。
